Merger Notification - Announcement according to § 10 Cartel Act
HarbourVest Partners, L.P.; Azurity Pharmaceuticals, Inc.; Covis-Gruppe S.à r.l
BWB/Z-6957
On 03.06.2025 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
HarbourVest Partners, LLC intends to acquire, via funds managed by it, indirect non-controlling economic interests without voting rights of at least 25% but less than 50% in CutisPharma Holdings, Inc. and thus as actual target company in Azurity Pharmaceuticals, Inc.
The Transaction concerns the market for pharmaceuticals.
ÖNACE Code 2025: Manufacture of pharmaceutical products.
C - MANUFACTURING C 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations, C 21.1 - Manufacture of basic pharmaceutical products, C 21.10 - Manufacture of basic pharmaceutical products, C 21.2 - Manufacture of pharmaceutical preparations, C 21.20 - Manufacture of pharmaceutical preparations
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 01.07.2025.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 02.07.2025 .